Luye Pharma Reports Successful Phase I Trials of Novel Anti-depressant

Luye Pharma, a China R&D-based company, has completed three China Phase I trials of a novel anti-depressant (LY03005), a serotonin-norepinephrine-dopamine triple reuptake inhibitor. The molecule, ansofaxine hydrochloride extended release tablets, passed all three tests. Luye, which holds IP for the drug, is concurrently developing LY03005 for China and the US markets, with a Phase I trial underway in the US. More details.... Stock Symbol: (HK: 2186) Share this with colleagues: // //